| 14.68 0 (0%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.29 | 1-year : | 17.41 |
| Resists | First : | 14.8 | Second : | 14.9 |
| Pivot price | 14.7  |
|||
| Supports | First : | 14.64 | Second : | 12.18 |
| MAs | MA(5) : | 14.68 |
MA(20) : | 14.71 |
| MA(100) : | 13.88 |
MA(250) : | 12.93 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 6.3 |
| RSI | RSI(14): 52.7 | |||
| 52-week | High : | 15.89 | Low : | 11.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MACK ] has closed above bottom band by 22.3%. Bollinger Bands are 83.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.74 - 14.82 | 14.82 - 14.88 |
| Low: | 14.46 - 14.57 | 14.57 - 14.65 |
| Close: | 14.54 - 14.69 | 14.69 - 14.81 |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Thu, 18 Apr 2024
Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 12.6% - Yahoo Movies Canada
Wed, 17 Apr 2024
Retail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds ... - Yahoo Movies Canada
Sat, 13 Apr 2024
A Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider increased their holdings by 43% last year - Yahoo Movies UK
Wed, 03 Apr 2024
Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Passes Above 200-Day Moving Average of $13.29 - MarketBeat
Wed, 27 Mar 2024
Merrimack Receives $225 Million Milestone Payment from Ipsen - Business Wire
Fri, 08 Mar 2024
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 66.6 (%) |
| Shares Short | 723 (K) |
| Shares Short P.Month | 774 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -7 % |
| Return on Equity (ttm) | -6.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -183.51 |
| PEG Ratio | 0 |
| Price to Book value | 11.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -140.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|